[144] Emergent BioSolutions Inc. SEC Filing
Emergent BioSolutions filed a Form 144 reporting a proposed sale of 30,608 common shares with an aggregate market value of
Emergent BioSolutions ha presentato un modulo Form 144 riferendo una vendita proposta di 30.608 azioni ordinarie con un valore di mercato aggregato di
La dichiarazione indica che le azioni sono state ricevute come azioni limitate in molteplici premi da parte dell’emittente tra
Il dichiarante non rappresenta alcuna informazione materialmente non pubblica non disclosure e non riporta vendite di titoli dell’emittente negli ultimi tre mesi.
Emergent BioSolutions presentó un Form 144 informando una venta propuesta de 30,608 acciones comunes con un valor de mercado agregado de
La presentación muestra que las acciones fueron recibidas como acciones restringidas en múltiples adjudicaciones del emisor entre
El presentante no reporta información material no pública no divulgada y no informa ventas de valores del emisor en los últimos tres meses.
Emergent BioSolutions은 Form 144를 제출하여 30,608 주의 보통주 매매 제안을 보고했으며 총 시가가
공시에는 주식이 발행자로부터 2023년 4월 7일에서 2024년 12월 8일 사이에 여러 차례의 부여로 제한주로 수령되었으며, 단일 가장 큰 부여는 26,779 주로
서명자는 비공개로 공개되지 않은 중요한 정보가 없으며 지난 3개월 동안 발행자 증권의 매매를 보고하지 않는다.
Emergent BioSolutions a déposé un formulaire 144 signalant une vente proposée de 30 608 actions ordinaires avec une valeur marchande agrégée de
Le dépôt montre que les actions ont été reçues sous forme d’actions restreintes lors de plusieurs attributions de l’émetteur entre
Le signataire déclare ne disposer d’aucune information matérielle non publique non divulguée et ne rapporte aucune vente de valeurs mobilières de l’émetteur au cours des trois derniers mois.
Emergent BioSolutions hat ein Form 144 eingereicht und einen vorgeschlagenen Verkauf von 30.608 Stammaktien mit einem aggregierten Marktwert von
Die Einreichung zeigt, dass die Aktien als eingeschränkte Aktien in mehreren Zuteilungen vom Emittenten zwischen
Der Melder gibt an, keine unangekündigten materiellen nicht-öffentlichen Informationen zu besitzen und meldet in den letzten drei Monaten keine Verkäufe von Emittentenwerten.
قدمت Emergent BioSolutions نموذج 144 يُبلغ عن بيع مقترح لـ 30,608 سهمًا عاديًا بقيمة سوقية إجمالية قدرها
يظهر الإبلاغ أن الأسهم قد تم تلقيها كأسهم مقيدة في منح متعددة من المُصدر بين
المقدم لا يمثل أي معلومات مادية غير منشورة وغير معلنة ولا يذكر أي مبيعات لأسهم المصدر في الأشهر الثلاثة الماضية.
Emergent BioSolutions 已提交 Form 144，报告拟议出售 30,608 股普通股，合计市值
公告显示这些股票是在发行方于
申报人表示不存在未披露的重要非公开信息，且在过去三个月内未报告发行人证券的销售。
- Clear disclosure of the proposed sale amount: 30,608 shares valued at
$306,080.00 - Securities acquired as restricted stock from the issuer across dated grants, showing legitimate insider holdings
- No sales in the prior three months reported, indicating this is not part of an ongoing rapid-disposition pattern
- Sale represents insider liquidity, which some investors may view neutrally or unfavorably depending on timing
- Proposed sale date is several months out (
10/07/2025 ), creating uncertainty until execution is reported
Insights
TL;DR: An insider plans a modest sale of restricted shares totaling
The filing indicates the sale is small relative to total shares outstanding (30,608 versus 53,351,099 outstanding), and the securities were acquired as restricted stock across five grant dates from
Key dependencies include the exact execution date around
TL;DR: The filer affirms no material nonpublic information and shows no recent sales, suggesting routine insider liquidity rather than unusual activity.
The disclosure lists multiple restricted-stock acquisitions from the issuer and no aggregated sales in the prior three months, aligning with standard Rule 144 notice practice when insiders sell vested restricted shares. The representation about lack of material undisclosed information is a required attestation on the form.
Watch for the subsequent Form 4 or broker-reported trades after
Emergent BioSolutions ha presentato un modulo Form 144 riferendo una vendita proposta di 30.608 azioni ordinarie con un valore di mercato aggregato di
La dichiarazione indica che le azioni sono state ricevute come azioni limitate in molteplici premi da parte dell’emittente tra
Il dichiarante non rappresenta alcuna informazione materialmente non pubblica non disclosure e non riporta vendite di titoli dell’emittente negli ultimi tre mesi.
Emergent BioSolutions presentó un Form 144 informando una venta propuesta de 30,608 acciones comunes con un valor de mercado agregado de
La presentación muestra que las acciones fueron recibidas como acciones restringidas en múltiples adjudicaciones del emisor entre
El presentante no reporta información material no pública no divulgada y no informa ventas de valores del emisor en los últimos tres meses.
Emergent BioSolutions은 Form 144를 제출하여 30,608 주의 보통주 매매 제안을 보고했으며 총 시가가
공시에는 주식이 발행자로부터 2023년 4월 7일에서 2024년 12월 8일 사이에 여러 차례의 부여로 제한주로 수령되었으며, 단일 가장 큰 부여는 26,779 주로
서명자는 비공개로 공개되지 않은 중요한 정보가 없으며 지난 3개월 동안 발행자 증권의 매매를 보고하지 않는다.
Emergent BioSolutions a déposé un formulaire 144 signalant une vente proposée de 30 608 actions ordinaires avec une valeur marchande agrégée de
Le dépôt montre que les actions ont été reçues sous forme d’actions restreintes lors de plusieurs attributions de l’émetteur entre
Le signataire déclare ne disposer d’aucune information matérielle non publique non divulguée et ne rapporte aucune vente de valeurs mobilières de l’émetteur au cours des trois derniers mois.
Emergent BioSolutions hat ein Form 144 eingereicht und einen vorgeschlagenen Verkauf von 30.608 Stammaktien mit einem aggregierten Marktwert von
Die Einreichung zeigt, dass die Aktien als eingeschränkte Aktien in mehreren Zuteilungen vom Emittenten zwischen
Der Melder gibt an, keine unangekündigten materiellen nicht-öffentlichen Informationen zu besitzen und meldet in den letzten drei Monaten keine Verkäufe von Emittentenwerten.
FAQ
What does Emergent BioSolutions (EBS) report in this Form 144?
The filing reports a proposed sale of 30,608 common shares with an aggregate market value of
How were the shares being sold acquired by the filer?
The shares were acquired as restricted stock in multiple grants from the issuer on dates between
Does the filing report recent sales of EBS securities by the filer?
No. The Form 144 states "Nothing to Report" for securities sold during the past three months.
What does the filer represent about material nonpublic information?
By signing the notice, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Through which broker will the sale be executed?
The broker named is Morgan Stanley Smith Barney LLC, address listed as 1 New York Plaza, New York, NY, for execution on the NYSE.
